Presenting on the above topic is Yamada Ei, President and CEO, AnGes MG, Japan. He will be speaking at 5th Annual BioPharma Asia Convention 2012, held on 19th to 22nd March 2012 at Marina Bay Sands, Singapore. He will be conducting an on-floor seminar at Theatre 3 at 13:00 on the 20th of March.
Here is a short abstract on what he will be speaking on:
In addition to PAD by HGF genetic medicine, we are challenging on a new therapy of lymphedema by HGF gene medicine. We could obtain the good results of the preclinical study including efficacy and safety by the animal model. We are planning to start the Phase I/IIa clinical study in this year to establish POC as soon as possible.
Further, we have been starting the Phase I/IIa clinical study of oral immunization with Lactobacillus casei vaccine expressing human papilloma virus (HPV) type 16 E7 to induce mucosal cytotoxic lymphocytes against HPV type 16 E7, conducting together with BioLeaders Corporation and Genolac BL. We could have the good results from the study in the HPV infected high-grade cervical intraepithelial neoplasia patients.